Fig. 1 · Structure

Documents & Downloads

PJ34

Cat. No. A15215 CAS 344458-19-1

PARP inhibitor

PJ34 is a novel potent specific inhibitor of PARP-l/2 with EC50 of 20 nM.

In Stock

Publications for PJ34

1 publication citing this product

  1. Tim J Wigle, .et al. , Cell Chem Biol, 2020, Jul 16;27(7):877-887 PMID: 32679093

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PJ34 inhibits multiple PARP-family enzymes. In a comparative biochemical panel, reported IC50 values were 10.9 nM for full-length PARP1 and 33.5 nM for full-length PARP2, with additional activity against other PARPs and tankyrases. Potency depended on the enzyme construct. This broad profile limits attribution of PJ34 responses specifically to PARP1. [1]

A TNKS1 catalytic-domain crystal structure resolved at 2.0 Å places PJ34 in the NAD+ donor pocket. Two ligand molecules occupy its nicotinamide and adenosine regions in this crystal model; this does not establish physiological binding stoichiometry. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PARP IC50 110 nM
PARP-2 IC50 86 nM
PARP-1 IC50 110 nM

Cellular Effect

Cell Line Activity Value Description Reference
HeLa IC50 20 nM Inhibition of PARP1 in human HeLa cells by fluid scintillation counting using [adenylated-32P]NAD as substrate [PMID: 18713665]
MEF IC50 13.2 μM Antiproliferative activity against MEF cells harboring Brca1 deletion mutant at exon 11 assessed as cell viability after 72 hrs by MTT assay [PMID: 22365563]
MEF IC50 19.8 μM Antiproliferative activity against wild type MEF cells assessed as cell viability after 72 hrs by MTT assay [PMID: 22365563]
Sf9 IC50 14.7 nM Inhibition of full length human N-terminal His-tagged PARP2 expressed in baculovirus infected Sf9 cells using histone H3.3 as substrate incubated for 20 mins followed by [32P[-NAD+ addition and further incubated for 1 hr by liquid scintillation counter [PMID: 32435397]
Sf9 IC50 9.1 nM Inhibition of full length human C-terminal His-tagged PARP1 expressed in baculovirus infected Sf9 cells using chicken core histone as substrate incubated for 20 mins followed by [32P[-NAD+ addition and further incubated for 1 hr by liquid scintillation co [PMID: 32435397]

In Vitro Studies

In HEK293 cells, PJ34 pretreatment reduced H2O2-induced poly(ADP-ribose) immunoreactivity over a displayed 0.1–10 µM series. This cellular activity readout supports PAR suppression under the tested conditions but does not establish selective PARP1 inhibition or an antiproliferative effect. [1]

PJ34 inhibition across PARP-family enzyme constructs

Biochemical assay · Purified human PARP-family full-length enzymes and catalytic-domain constructs listed in Table 2 [1]

A single comparative enzyme-profiling design supports broad PARP-family inhibition. Potency varies by enzyme and construct; weaker PARP10/14/15 responses are retained. Individual enzyme rows are endpoints of this study, not separate studies.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Full-length PARP1 ADP-ribosylation inhibitionIC50; pIC50 10.9 nM; pIC50 7.96 ± 0.10[1]
PARP1 ART fragment ADP-ribosylation inhibitionIC50; pIC50 61 nM; pIC50 7.22 ± 0.13[1]
Full-length PARP2 ADP-ribosylation inhibitionIC50; pIC50 33.5 nM; pIC50 7.48 ± 0.06[1]
PARP2 ART fragment ADP-ribosylation inhibitionIC50; pIC50 382 nM; pIC50 6.42 ± 0.06[1]
Full-length PARP3 ADP-ribosylation inhibitionIC50; pIC50 1430 nM; pIC50 5.84 ± 0.15[1]
TNKS1 ART fragment ADP-ribosylation inhibitionIC50; pIC50 1690 nM; pIC50 5.77 ± 0.05[1]
TNKS2 ART fragment ADP-ribosylation inhibitionIC50; pIC50 2900 nM; pIC50 5.53 ± 0.10[1]
Full-length PARP10 ADP-ribosylation inhibitionIC50; pIC50 5800 nM; pIC50 5.23 ± 0.10[1]
PARP10 ART fragment ADP-ribosylation inhibitionIC50; pIC50 6800 nM; pIC50 5.17 ± 0.15[1]
PARP12 ART fragment ADP-ribosylation inhibitionIC50; pIC50 230 nM; pIC50 6.65 ± 0.11[1]
PARP14 ART fragment ADP-ribosylation inhibitionIC50; pIC50 4200 nM; pIC50 5.38 ± 0.05[1]
PARP15 ART fragment ADP-ribosylation inhibitionIC50; pIC50 9000 nM; pIC50 5.05 ± 0.15[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; assay IC50 values are endpoints, not treatment recommendations.
Exposure duration
15 min preincubation before NAD+ addition; reaction duration not specified in acquired main-text assay description.
Method
ADP-ribosylation assay with NAD+ at each construct’s KM or below; CLARIOstar reader.
Vehicle
1% DMSO final; control reactions used DMSO from the same batch.
Reported limits
Detailed SI assay settings and material certificates were not retrieved. Per-enzyme repetition counts are not supplied in the acquired table: general methods report 2 or 3 technical replicate series and 1–5 repetitions.
Methods and source locations

Compound reported in the paper: PJ34; Compound label in the paper: PJ34

Literature results for the PJ34 parent compound as tested in solution; no validation of this free-base catalog lot, no salt conversion, and no assumption of formulation equivalence.

Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics

Full-length PARP1 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP1 row

PARP1 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP1 ART fragment row

Full-length PARP2 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP2 row

PARP2 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP2 ART fragment row

Full-length PARP3 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP3 row

TNKS1 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; TNKS1 ART fragment row

TNKS2 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; TNKS2 ART fragment row

Full-length PARP10 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP10 row

PARP10 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP10 ART fragment row

PARP12 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP12 ART fragment row

PARP14 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP14 ART fragment row

PARP15 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP15 ART fragment row

Suppression of induced cellular PAR signal

Cell-based study · HEK293 cells challenged with H2O2 [1]

PJ34 pretreatment reduced induced PAR immunoreactivity across the displayed concentration series. Vehicle-treated stimulated and unstimulated lanes and an actin blot provide assay context. This is a cellular PAR readout, not PJ34 CETSA, a viability assay, or proof of selective PARP1 inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
H2O2-induced cellular poly(ADP-ribose) signalQualitative immunoblot response Concentration-dependent reduction of PAR immunoreactivity; no cellular IC50 calculated here.[1]

Literature-Reported Treatment Conditions

Treatment concentration
PJ34: 0.1, 0.3, 1, 3 and 10 µM; zero-compound stimulated and unstimulated controls shown.
Exposure duration
30 min compound pretreatment, followed by 15 min H2O2 stimulation.
Method
H2O2 challenge at 500 µM followed by cellular lysate Western blotting.
Vehicle
DMSO vehicle; final cellular vehicle percentage not specified in this assay subsection.
Co-treatment
H2O2 is an assay stimulus; XAV939 is a separate comparator series, not combined with PJ34.
Reported limits
No numerical densitometry, PJ34 cellular IC50 or replicate count stated for Figure 4E in the acquired main text/caption. Compound removal during challenge is not specified.
Methods and source locations

Compound reported in the paper: PJ34; Compound label in the paper: PJ34

Literature results for the PJ34 parent compound as tested in solution; no validation of this free-base catalog lot, no salt conversion, and no assumption of formulation equivalence.

Figure 4E (viewed Western blot) and caption; Experimental Section: Cellular PARP Activity Assay

H2O2-induced cellular poly(ADP-ribose) signal: Anti-PAR (10H) Western blot with actin loading-control blot. — Figure 4E (viewed Western blot) and caption; Experimental Section: Cellular PARP Activity Assay

PJ34 binding within the TNKS1 NAD+ donor pocket

Biochemical assay · Human TNKS1 catalytic PARP domain, residues Gly1105–Thr1327; crystal structure PDB 3UH2 [2]

The crystal model places two PJ34 molecules per protein molecule in the NAD+ donor pocket, one in the nicotinamide region and one in the adenosine region. The model includes an open D-loop relative to the previously determined unliganded structure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TNKS1–PJ34 crystal structure resolutionX-ray resolution 2.0 Å[2]
PJ34 binding positions in the refined crystal modelStructural occupancy Two PJ34 molecules per TNKS1 protein molecule in the crystal model: nicotinamide and adenosine regions of the NAD+ donor pocket.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM PJ34 added for cocrystallization.
Method
Cocrystallization with TNKS1 catalytic domain and X-ray structure determination.
Reported limits
Supplied salt and PJ34 stock vehicle are not specified in the acquired crystallization subsection; no biological treatment course applies.
Methods and source locations

Compound reported in the paper: PJ34; Compound label in the paper: PJ34

Structural binding evidence for PJ34; crystallization concentration is not a treatment dose or cellular potency, and crystal occupancy is not physiological stoichiometry.

Sections 2.2–2.4 and 3.1; Table 1, TNKS1–PJ34 column; Figure 1a and Figure 2a,b (viewed)

TNKS1–PJ34 crystal structure resolution: X-ray crystallography; Table 1 reports Rcryst/Rfree 0.175/0.217. — Sections 2.2–2.4 and 3.1; Table 1, TNKS1–PJ34 column; Figure 1a and Figure 2a,b (viewed)

PJ34 binding positions in the refined crystal model: Refined structure and Figure 2a; unliganded structure comparison in Figure 2b. Not an equilibrium stoichiometry measurement. — Sections 2.2–2.4 and 3.1; Table 1, TNKS1–PJ34 column; Figure 1a and Figure 2a,b (viewed)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 344458-19-1
Applications PARP inhibitor
Formula C17H17N3O2
Molecular Weight 295.34
SMILES
CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Thorsell AG, Ekblad T, Karlberg T, et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors Journal of medicinal chemistry (2017). PMID: 28001384 DOI: 10.1021/acs.jmedchem.6b00990 Source material
  2. [2] Kirby CA, Cheung A, Fazal A, et al. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939 Acta crystallographica. Section F, Structural biology and crystallization communications (2012). PMID: 22297980 DOI: 10.1107/s1744309111051219 Source material

Publications

1 publication citing this product

  1. Tim J Wigle, .et al. , Cell Chem Biol, 2020, Jul 16;27(7):877-887 PMID: 32679093
Press to skip carousel

You May Also Consider

A-966492

A10019 CAS 934162-61-5

A-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
The price depends on the options chosen on the product page

Starting at $20.00

View Sizes
Veliparib

A10026 CAS 912444-00-9

ABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
Rucaparib (AG-014699) phosphate

A10045 CAS 459868-92-9

AG-014699 (Rucaparib) is a PARP inhibitor that inhibits poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
AG14361

A10046 CAS 328543-09-5

AG14361 is a potent PARP inhibitor, enhanced TMZ cytotoxicity in MMR(mismatch repair)-proficient / deficient cells.
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes
Olaparib

A10111 CAS 763113-22-0

Olaparib (AZD2281) is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
Iniparib

A10164 CAS 160003-66-7

BSI-201 is a potent inhibitor of PARP-1 and has been shown to cross the blood-brain barrier.
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes
3-Aminobenzamide

A10475 CAS 3544-24-9

3-Aminobenzamide is a novel PARP inhibitor, known to sensitize cells to radiation in vitro by inhibiting the repair of DNA damage.
The price depends on the options chosen on the product page

Starting at $20.00

View Sizes
XAV 939

A10994 CAS 284028-89-3

XAV 939 is a TNKS inhibitor (IC50 values are 0.011 and 0.004 μM for TNKS1 and TNKS2 respectively).
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes

Added to your cart

View Cart Checkout
Loading...